Nurix Therapeutics Inc (NAS:NRIX)

$ 22.11 0.88 (4.15%) Market Cap: 1.57 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 3.94 GF Score: 48/100

Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Nurix Therapeutics Inc at the ASH Annual Meeting Transcript
Dec 12, 2023
Nurix Therapeutics Inc to Announce Strategic Collaboration with Seagen Transcript
Sep 07, 2023
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Nurix Therapeutics Inc Annual Shareholders Meeting Transcript
May 04, 2023
Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Nurix Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Nurix Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion Transcript
Feb 21, 2023
Nurix Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) Transcript
Feb 21, 2023
Nurix Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Nurix Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Nurix Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Nurix Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 13, 2022
Nurix Therapeutics Inc at Wells Fargo Healthcare Conference Transcript
Sep 07, 2022
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 18, 2022
Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Nurix Therapeutics Inc at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) Transcript
Mar 16, 2022
Nurix Therapeutics Inc Development Under Stress - Finding New Ubiquitylation Enzymes for Therapeutic Benefit Transcript
Oct 13, 2020

Nurix Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 02:40PM GMT

Release Date Price: $9.34 (+1.41%)

Transcript

Mark Breidenbach

Oppenheimer & Co. Inc. - Analyst

All right. Hello, everyone. Thanks so much for joining us on day two of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the biotech analysts here at Oppenheimer. The next presenting company is Nurix Therapeutics, which is developing a pipeline of targeted protein degraders and E3 ligase inhibitors for cancer and autoimmune disease.

And joining us to walk us through the story today is the company's CEO, Arthur Sands. We'll try and leave a few minutes at the end for Q&A. I would encourage anyone in the audience who has questions to make use of that button on your screen to submit a question. And with that said, let's just jump right into the presentation. Arthur, the mic is yours.

Arthur Sands

Nurix Therapeutics, Inc. - President, CEO, & Board Director

Great. Thank you, Mark. It's a pleasure to be here today. Let me get my slides in order here and get started. I will be making certain forward-looking statements. So I remind you and refer you to our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.